Jardiance Pre-Surgery Hold Window: Empagliflozin Perioperative Guidelines

Empagliflozin, marketed as Jardiance, is an oral SGLT2 (sodium-glucose cotransporter-2) inhibitor available in 10 mg and 25 mg tablet formulations. The FDA has approved it for multiple indications including type 2 diabetes management, reduction of cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease, heart failure with either reduced or preserved ejection fraction, and chronic kidney disease. The multiple approved uses mean that surgical patients taking empagliflozin may do so for indications unrelated to glycemic management, a distinction that influences perioperative management decisions.

Guideline bodies including the American Diabetes Association and the Joint British Diabetes Societies recommend holding empagliflozin for 3 to 4 days before elective surgery that requires general or neuraxial anesthesia, regardless of why the drug was prescribed. The reason is euglycemic diabetic ketoacidosis (euDKA), a rare complication in which ketoacidosis develops without the marked hyperglycemia clinicians normally rely on as a warning sign. The exact duration (3 versus 4 days) is not settled by a single high-quality trial; it is a consensus judgment based on the drug's pharmacodynamic tail, case reports, and procedural risk, which is why the recommended window differs slightly by guideline and by procedure type.

Why the hold window exists

Empagliflozin blocks SGLT2 in the renal proximal tubule, increasing urinary glucose loss. This is the mechanism behind its glucose-lowering and cardiorenal effects, but it also shifts the body toward fatty-acid oxidation and ketone production. Surgery independently stresses glucose and hormone regulation: fasting, catecholamine release, and anesthetic agents reduce insulin activity and raise glucagon. In a patient already taking an SGLT2 inhibitor, this combination can drive ketogenesis even when glucose stays in a range that would not normally trigger concern, sometimes below 200 mg/dL [2].

The euglycemic DKA problem

Euglycemic DKA is diagnosed by low arterial pH and elevated serum ketones in a patient whose glucose is not markedly elevated, typically under 250 mg/dL. Because the glucose number looks reassuring, the diagnosis is easy to miss in a post-surgical patient with nonspecific nausea, fatigue, or abdominal discomfort [2][3]. The FDA issued a drug safety communication on SGLT2 inhibitor-associated DKA in 2015 and reinforced the warning in an updated communication in 2020, noting that factors including surgery, reduced food intake, and acute illness can precipitate the condition across the drug class.

Systematic reviews of published perioperative euDKA cases associated with SGLT2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, describe cases clustering in the first few days after the last dose and after procedures involving fasting, bowel preparation, or major fluid shifts. Exact case counts and time-to-onset figures vary between reviews and are worth checking against the primary review article rather than treated as a fixed number, since methodology and case ascertainment differ across publications.

Why the window extends beyond the drug's plasma half-life

Empagliflozin's terminal half-life is approximately 12 to 13 hours according to the FDA-approved prescribing information, so plasma drug levels fall substantially within a day of the last dose [7]. However, the downstream effect on renal glucose handling and ketone metabolism appears to persist longer than plasma levels alone would suggest, which is the pharmacodynamic rationale offered in perioperative reviews for a hold window of several days rather than one day. This distinction, between how fast the drug clears and how long its metabolic effect lingers, is the reason a single-day hold was abandoned in favor of a multi-day one.

What current guidance says

American Diabetes Association

The ADA's Standards of Care in Diabetes addresses inpatient and perioperative diabetes management and recommends holding SGLT2 inhibitors, including empagliflozin, for at least 3 to 4 days before surgery requiring general, spinal, or epidural anesthesia, applying this regardless of whether the drug was prescribed for glycemic control, heart failure, or kidney disease [8]. Readers who need the exact current wording should check the current year's Section 16 directly, since annual updates can adjust specific thresholds.

Joint British Diabetes Societies

The JBDS inpatient guidance addresses SGLT2 inhibitor management around surgery and recommends a hold of several days before elective procedures, with closer attention (including ketone checks) for medium- and high-risk procedures [9]. As with the ADA guidance, the precise duration language should be checked against the current published guideline rather than assumed to be identical wording across revisions.

Where guidance is less settled

Statements about a specific society issuing a formal "3-day for low-risk, 4-day for bowel prep or prolonged fasting" consensus could not be independently verified against a primary source for this draft and should be confirmed by the reviewing clinician before publication. Until confirmed, treat the risk-stratified framework below as a reasonable synthesis of the mechanism and the ADA/JBDS hold windows, not as a direct quotation from any single named society statement.

A decision framework for hold duration

The single hardest practical question is not "should I hold Jardiance" but "for how long, given this specific patient and this specific procedure." The table below is an original synthesis built from the mechanism above and the ADA/JBDS hold ranges. It is a decision aid for discussion with the prescribing clinician and anesthesia team, not a substitute for institutional protocol.

If any box in the right two columns cannot be completed (no ketone meter available, uncertain last-dose date, unclear renal function), the safer default is to treat the case as higher risk and extend the hold or delay the elective procedure rather than proceed on an assumption.

Managing glucose during the hold

Stopping empagliflozin does not remove the need for glucose management. Empagliflozin's own contribution to glycemic control is modest compared with insulin or sulfonylureas, so a short interruption of 3 to 4 days is generally well tolerated from a glucose-control standpoint in patients on stable combination regimens, though this should be individualized rather than assumed. Perioperative glucose targets of roughly 140 to 180 mg/dL are commonly used for hospitalized surgical patients; tighter targets are sometimes used in cardiac surgery, but evidence for very tight glycemic control (under 110 mg/dL) in general surgical populations has been contested since the NICE-SUGAR trial found harm from intensive glucose control in critically ill patients [11].

Ketone monitoring

Point-of-care blood ketone testing on the day of surgery is a reasonable safety check for any patient with recent SGLT2 inhibitor use, even after a compliant hold, because individual pharmacodynamic variability means some patients clear the ketogenic effect more slowly than others. A clinically meaningful ketone elevation on the day of surgery should prompt discussion with the surgical and anesthesia team about delaying an elective procedure; the exact threshold used for that decision should follow institutional protocol rather than a single number applied uniformly.

Emergency surgery: no hold window available

When surgery cannot wait and the patient has taken empagliflozin within the recommended hold window, ketone status becomes the deciding factor, not the surgery schedule. A commonly recommended approach, consistent with JBDS-style inpatient diabetes guidance, includes:

1. Check blood ketones and, if elevated, arterial or venous blood gas immediately on arrival, independent of the glucose reading.
2. If euDKA criteria are met, treat with intravenous dextrose-containing fluids and an insulin infusion to suppress ketogenesis before proceeding with anything short of immediately life-saving surgery.
3. Recheck ketones at intervals through the perioperative period.
4. Do not restart empagliflozin until the patient is eating, volume-stable, and ketones have normalized [9].

Exact protocol details (infusion rates, specific ketone or pH cutoffs used at a given institution) belong to local emergency and endocrinology protocols and should be confirmed locally rather than taken from this article.

Why continuing the drug matters once the hold ends

The perioperative hold is meant to be temporary. Empagliflozin has trial evidence supporting meaningful cardiovascular and renal benefit in appropriate populations: the EMPA-REG OUTCOME trial (N=7,020) in people with type 2 diabetes and established cardiovascular disease showed a reduction in cardiovascular death compared with placebo [12], with a companion renal analysis showing reduced risk of incident or worsening nephropathy [13]. In heart failure populations, EMPEROR-Reduced showed benefit on cardiovascular death or heart failure hospitalization in patients with reduced ejection fraction [14], and EMPEROR-Preserved showed a similar benefit in patients with preserved ejection fraction [15]. These trials support the long-term case for continuing the drug once it is safe to restart; they are not perioperative safety trials and do not by themselves establish an optimal hold duration.

Patients taking empagliflozin for heart failure deserve particular attention at both ends of the hold. The drug has mild diuretic effects that support fluid management in heart failure; abrupt interruption around a major operation, in a patient who is also receiving surgical fluids, can complicate volume assessment in either direction. Coordinating hold and restart timing with the cardiology team is reasonable for these patients, though the specific approach should be individualized rather than protocolized here.

Restarting after surgery

Empagliflozin should not be restarted automatically at a fixed hour. A reasonable set of criteria, drawn from ADA and JBDS-style inpatient guidance, is that all of the following should be true before the first restarted dose [8][9]:

• The patient is tolerating oral food and fluids
• Renal function has returned to a level consistent with the drug's approved use (check the current FDA label for the specific eGFR thresholds tied to the diabetes, heart failure, and kidney disease indications, since these differ by indication)
• There is no evidence of acute kidney injury on post-operative labs
• Ketones are not elevated
• The patient is not on IV dextrose or insulin infusions that would make ketone interpretation unreliable

In most uncomplicated elective surgery these criteria are met within 24 to 48 hours. After major abdominal surgery, prolonged ileus, or other complications, restart is often deferred several days longer, guided by the surgical and medical team's assessment rather than a fixed calendar rule.

What is established, what is plausible, and what is not established

Established: SGLT2 inhibitors as a class, including empagliflozin, are associated with a risk of euglycemic DKA, and this risk is described in the FDA's own drug safety communications [4]. Holding the drug for several days before major anesthesia, and confirming ketone status when compliance is uncertain, is standard practice recommended by major diabetes care guidelines [8][9].

Plausible but not rigorously quantified for empagliflozin specifically: The idea that low body weight, very low-carbohydrate intake, or prior ketosis raises perioperative euDKA risk is mechanistically reasonable and appears in perioperative reviews, but a precise, well-replicated risk estimate specific to empagliflozin was not available in the sources reviewed for this draft. Treat any specific odds ratio or percentage tied to this idea as unverified until confirmed against the primary study.

Not established: There is no trial directly comparing a 3-day hold against a 4-day hold for empagliflozin measuring euDKA incidence as the outcome. The 3-versus-4-day distinction used across guidelines is a consensus judgment, not a result from a randomized comparison, and readers should not treat either number as precisely validated.

Practical checklist for the pre-anesthesia visit

• Confirm empagliflozin is on the active medication list and document indication (diabetes, heart failure, or kidney disease)
• Set and document a specific last-dose date, 3 to 4 days before the procedure depending on the risk category above
• Give the patient written instructions with the specific date, not only verbal counseling, since medication instructions given only verbally are recognized to be forgotten or misapplied by a meaningful share of surgical patients; institutions should track their own no-recall rate rather than relying on this article for a specific figure
• On the day of surgery, confirm the last dose date and consider a point-of-care ketone check if compliance or fasting duration is uncertain
• Post-operatively, check renal function and clinical status before restarting, using the restart criteria above

Common questions

This article summarizes guideline and trial literature for general education. It is pending qualified clinical review and does not replace individualized guidance from the prescribing physician, surgeon, and anesthesia team, who should confirm hold and restart timing based on the specific procedure and patient.